Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys (ETR:MOR) in a report issued on Wednesday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
A number of other analysts have also recently commented on the stock. Deutsche Bank set a €133.00 ($154.65) price target on shares of MorphoSys and gave the company a buy rating in a research note on Thursday, July 18th. Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a sell rating in a research note on Monday, June 24th. Independent Research set a €96.00 ($111.63) price target on shares of MorphoSys and gave the company a neutral rating in a research note on Thursday, July 4th. Berenberg Bank set a €150.00 ($174.42) price target on shares of MorphoSys and gave the company a buy rating in a research note on Monday, August 5th. Finally, JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of MorphoSys and gave the company a buy rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of €113.56 ($132.04).
Shares of MOR stock opened at €111.00 ($129.07) on Wednesday. The stock has a market cap of $3.50 billion and a PE ratio of -59.74. The company has a quick ratio of 7.53, a current ratio of 7.75 and a debt-to-equity ratio of 8.65. The company’s 50 day simple moving average is €96.61. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €111.00 ($129.07).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Article: What is the Fibonacci sequence?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.